Metastatic patterns at autopsy in patients with ovarian carcinoma

Güth, Uwe; Huang, Dorothy Jane; Bauer, Gregor; Stieger, Marco; Wight, Edward; Singer, Gad

doi:10.1002/cncr.22919

Cited by 61 publications

(60 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] In most autopsy reports from the last 3 decades that deal with the metastatic pattern of EOC the uterus is not listed as a metastatic site [6][7][8][9][10] probably because the patients underwent a hysterectomy before they died of the disease. In only one study of 100 autopsies of ovarian cancer 11 it is reported that the uterine serosa, the myometrium and the cervix were involved in 27%, 10%, and 3% respectively.…”

Section: Discussionmentioning

confidence: 99%

Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy

2010

View full text Add to dashboard Cite

Objective: Possible reasons for hysterectomy in the initial surgical management of advanced invasive epithelial ovarian carcinoma (EOC) might be a high frequency of uterine involvement and its impact on survival. The aim of the present study was to describe the frequency of uterine involvement and its association with survival in an unselected population of EOC patients who underwent hysterectomy. Methods: All incident cases of EOC diagnosed in Israeli Jewish women between March 1994 to June 1999, were identified within the framework of a nationwide case-control epidemiological study. The target population of the present report includes all stage II-IV EOC patients who had a uterus at the time of diagnosis. Of the 822 such patients, 695 fulfilled the inclusion criterion. Excluded were 141 patients for various reasons. The present analysis is based on the remaining 554 patients. Results: Uterine involvement was present in 291 (52.5%) of the patients and it was macroscopic in only 78 (14.1%). The serosa was the most common site of isolated metastases. Multivariate analysis showed that advanced stage significantly increased the risk for uterine involvement. The overall median survival with any uterine involvement was significantly lower compared to those with no involvement (38.9 months vs. 58.0 months; p＜0.001). Conclusion:There is an association between uterine involvement, whether macro-or microscopic, and lower survival even after hysterectomy although residual tumor could not be included in the analysis. Further studies are required to establish whether uterine involvement itself is an unfavorable risk factor or merely a marker of other unfavorable prognostic factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy

2010

View full text Add to dashboard Cite

show abstract

“…Ovu skupinu čine serozni i endometrioidni karcinom visokog gradusa, nediferencirani karcinom i karcinosarkom. Serozni karcinom visokog gradusa je najčešći, ne samo u ovoj skupini tumora, nego čini 70 % svih karcinoma jajnika i odgovoran je za 90 % smrti od ove bolesti 33 . Manje od 1 % seroznih karcinoma jajnika visokog gradusa u trenutku dijagnoze ograničeno je na jajnik 34 , a 5-godišnje preživ-ljenje pacijentica u IIIC stadiju bolesti, u kojem se najčešće prezentiraju, je samo 29 % 1,4 .…”

Section: Tip 2 Tumoriunclassified

“…Stoga se mogu dijagnosticirati u ranoj fazi s dosad razvijenim metodama probira koje se veći-nom temelje na transvaginalnom ultrazvučnom pregledu i mjerenjima serumske koncentracije CA 125 [8][9][10] . No, ovi tumori čine samo 25 % svih karcinoma jajnika, a odgovorni su za otprilike 10 % smrti od ove bolesti 33 . Nasuprot tome, tip 2 tumori čine 75 % svih karcinoma jajnika, a odgovorni su za 90 % letalnog ishoda bolesti.…”

unclassified

Recent concepts of ovarian cancer

2016

View full text Add to dashboard Cite

Sažetak. Karcinom jajnika je vodeći uzrok smrti među zloćudnim novotvorinama ženskog spolnog sustava. Usprkos pokušajima razvoja programa probira s ciljem ranog otkrivanja bolesti, kao i novim terapijskim pristupima, mortalitet nije značajno smanjen. Jedan od razloga ovog neuspjeha bio je slabo razumijevanje patogeneze karcinoma jajnika koji je smatran jedinstvenom bolešću. Nove spoznaje pokazuju da je karcinom jajnika vrlo heterogena bolest, koja se na temelju kliničkopatoloških karakteristika te molekularnih i genetičkih promjena može podijeliti u dvije skupine: tip 1 i tip 2 tumori. Ovaj novi model patogeneze karcinoma jajnika danas ima važan klinički i terapijski značaj.Ključne riječi: karcinom jajnika; morfologija; patogeneza; terapija Abstract. Ovarian cancer is the most lethal gynecologic malignancy. Efforts to develop screening methods and new therapeutic approaches to reduce mortality have been unsuccessful. One of the main reasons for this is our lack of knowledge of the origin and pathogenesis of ovarian cancer. This led to the postulate that it is a single disease. Recent studies have shown that ovarian cancer is a heterogeneous disease composed of diverse types of tumors that can be classified based on clinicopathologic and molecular genetic features into two broad groups designated type 1 and type 2. This new model of pathogenesis of ovarian cancer has significant clinical and therapeutic implication.

show abstract

“…The liver is the fourth most common site of metastasis in recurrent ovarian cancer (OC) [1]: clinical data from living patients have shown an incidence of hepatic metastasis of approximately 9.4% [2]; moreover, several autopsy studies have indicated a major incidence of liver metastasis in relapsed OC ranging from 48% to 58.4% [1,2].…”

Section: Introductionmentioning

confidence: 99%

Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: case report and literature review

et al. 2011

View full text Add to dashboard Cite

Reactive lymphoid hyperplasia (RLH) is a rare, benign, lymphocytic tumour-like lesion reported in various organs. It has been previously identified in 18 cases in the English-language literature, but only 5 of them were related to oncological disease. No previous cases have been described of RLH occurring in ovarian cancer patients. We describe a case of hepatic RLH which developed in a patient treated for ovarian cancer 11 years previously. Radiological features on computed tomography (CT) scan and PET-CT (positron emission tomography-computed tomography) were strongly suggestive of oncological disease, in contrast to magnetic resonance imaging (MRI); the volume increment of the nodular lesion and the rise in carbohydrate antigen 125 corroborated the hypothesis of malignancy. The patient was subjected to resection of the 7th segment of the liver and the final histological report showed RLH. RLH should be considered in the presence of hepatic lesions in suspected ovarian cancer recurrence. Imaging techniques should be thoroughly investigated to exclude tumor recurrence promptly, in order to avoid unnecessary surgery.

show abstract

Metastatic patterns at autopsy in patients with ovarian carcinoma

Cited by 61 publications

References 18 publications

Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy

Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy

Recent concepts of ovarian cancer

Reactive lymphoid hyperplasia of liver mimicking late ovarian cancer recurrence: case report and literature review

Contact Info

Product

Resources

About